Prescient Therapeutics (ASX:PTX) continues to advance PTX-200 AML trial
Prescient Therapeutics (PTX) will progress to the next dose level of its Phase 1b clinical...
Prescient Therapeutics (PTX) will progress to the next dose level of its Phase 1b clinical...
The market for revolutionary CAR-T cancer treatments is expected to grow to USD 14 billion...
When JVC launched VHS videos in 1971, it started a consumer revolution that permanently altered...
Two ASX-listed ventures are among the companies now investing billions of dollars to develop an...
The burgeoning CAR T therapy industry has passed another significant milestone after the US Food...
Australian listed biotech company Prescient Therapeutics (ASX: PTX) is forging a path for other prospective...
StockTalk is a Stockhead video series featuring a roundtable of experts discussing a new investment topic each...
Several major pharmaceutical companies have cautioned they’re unable to widely use revolutionary CAR-T cancer treatments,...
There are several ASX stocks fighting cancer but only a few are addressing blood cancers....
Are you looking to add some exposure to the small side of the market to...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.